These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19679004

  • 21. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB.
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI.
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [Abstract] [Full Text] [Related]

  • 23. Economic burden of endometriosis.
    Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL.
    Fertil Steril; 2006 Dec; 86(6):1561-72. PubMed ID: 17056043
    [Abstract] [Full Text] [Related]

  • 24. Direct and indirect costs of asthma in school-age children.
    Wang LY, Zhong Y, Wheeler L.
    Prev Chronic Dis; 2005 Jan; 2(1):A11. PubMed ID: 15670464
    [Abstract] [Full Text] [Related]

  • 25. Pharmacoeconomics of antimicrobial therapy.
    Paladino JA.
    Am J Health Syst Pharm; 1999 Nov 15; 56(22 Suppl 3):S25-8. PubMed ID: 10580738
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J.
    Headache; 2005 Sep 15; 45(8):1012-22. PubMed ID: 16109115
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Direct and indirect costs of asthma in Canada, 1990.
    Krahn MD, Berka C, Langlois P, Detsky AS.
    CMAJ; 1996 Mar 15; 154(6):821-31. PubMed ID: 8634960
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Economic evaluation of ribosomal immunotherapy in patients with chronic ear, nose and throat and respiratory tract infections: results for Italy.
    Banz K, Thomas AM, Olivieri D.
    BioDrugs; 1998 Nov 15; 10(5):385-96. PubMed ID: 18020610
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F, Barbieri M, Dirodi B, Vitali Rosati G, Franco E.
    Ann Ig; 2013 Nov 15; 25(1):43-56. PubMed ID: 23435779
    [Abstract] [Full Text] [Related]

  • 36. Research needs in allergy: an EAACI position paper, in collaboration with EFA.
    Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V, Custovic A, Demonchy J, Demoly P, Eigenmann P, Gayraud J, Grattan C, Heffler E, Hellings PW, Jutel M, Knol E, Lötvall J, Muraro A, Poulsen LK, Roberts G, Schmid-Grendelmeier P, Skevaki C, Triggiani M, Vanree R, Werfel T, Flood B, Palkonen S, Savli R, Allegri P, Annesi-Maesano I, Annunziato F, Antolin-Amerigo D, Apfelbacher C, Blanca M, Bogacka E, Bonadonna P, Bonini M, Boyman O, Brockow K, Burney P, Buters J, Butiene I, Calderon M, Cardell LO, Caubet JC, Celenk S, Cichocka-Jarosz E, Cingi C, Couto M, Dejong N, Del Giacco S, Douladiris N, Fassio F, Fauquert JL, Fernandez J, Rivas MF, Ferrer M, Flohr C, Gardner J, Genuneit J, Gevaert P, Groblewska A, Hamelmann E, Hoffmann HJ, Hoffmann-Sommergruber K, Hovhannisyan L, Hox V, Jahnsen FL, Kalayci O, Kalpaklioglu AF, Kleine-Tebbe J, Konstantinou G, Kurowski M, Lau S, Lauener R, Lauerma A, Logan K, Magnan A, Makowska J, Makrinioti H, Mangina P, Manole F, Mari A, Mazon A, Mills C, Mingomataj E, Niggemann B, Nilsson G, Ollert M, O'Mahony L, O'Neil S, Pala G, Papi A, Passalacqua G, Perkin M, Pfaar O, Pitsios C, Quirce S, Raap U, Raulf-Heimsoth M, Rhyner C, Robson-Ansley P, Alves RR, Roje Z, Rondon C, Rudzeviciene O, Ruëff F, Rukhadze M, Rumi G, Sackesen C, Santos AF, Santucci A, Scharf C, Schmidt-Weber C, Schnyder B, Schwarze J, Senna G, Sergejeva S, Seys S, Siracusa A, Skypala I, Sokolowska M, Spertini F, Spiewak R, Sprikkelman A, Sturm G, Swoboda I, Terreehorst I, Toskala E, Traidl-Hoffmann C, Venter C, Vlieg-Boerstra B, Whitacker P, Worm M, Xepapadaki P, Akdis CA.
    Clin Transl Allergy; 2012 Nov 02; 2(1):21. PubMed ID: 23121771
    [Abstract] [Full Text] [Related]

  • 37. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.